Shares of drugmaker Sanofi (NASDAQ:SNY) failed to keep up with the broader market in 2013, and the stock is down nearly 8% year to date. Disappointing guidance and the recent FDA rejection of multiple sclerosis treatment Lemtrada have driven shares down. However, is the market being myopic? Could Sanofi be positioned for growth, and are its shares valued attractively compared to its Big Pharma peers? Analysts Max Macaluso and David Williamson discuss this dividend stock in the following video.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.